Answers are grounded in this paper and cite their sources.
New rank-based methods for analyzing data from multisite clinical trials are presented in the context of "mixed" linear models. In contrast to current rank methods, the new procedures test for a drug main effect in the presence of a random drug by site interaction (or drug by investigator interaction when there is only one investigator per site). Analogous procedures are also provided for the "fixed-effects" situation, and comparisons are made with current methods. The rationale for an analysis that assumes random investigator effects is described.
No takes yet. Share an insight, caveat, or question.
Boos et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: